Amneal

Quote
anonymous said:
2023 Performances Reviews will be a joke. If anyone should be put on a PIP or fired it’s the Medical folks involved in launching IPX. 2023 was geared towards the launch of that! It’s why you saw 1% Rytary growth. Instead we got reconfigured Territories and ran out of Rytary samples. Tough to get in front of customers when you can’t deliver what they ask for (Samples). Now we have new Territories with even more aggressive KPI expectations.
Who ever sets forecasts and goals should be put on a PIP till they get it right. Their failures in 23 will only be amplified in 24. They should have to report in every day explaining what they did all day followed by a weekly tracker of activity and messaging due every Friday by 6 pm
Finally if anyone is left from home office who was responsible for the Lyvispah relaunch needs to be gone. Especially anyone who promised fantastic medical coverage. How do you review the sales force when you finally admit it was a horrible drug and a horrible decision? Only 1 of the 3 COE winners was even in the division from start to finish. Since the launch failed do you give them all Needs Improvement? Absolutely ridiculous how they’ve been treated and most likely will be treated during this process.
Give a huge raise to the Biosims team. They are crushing it
Endo keeps putting up numbers. Whoever is in charge of their pricing strategy needs a raise. From my understanding those reps don’t make much so bump up their pay.
Click to expand...

The Endo ABD is covering his ass. We received an email from him laying out call metrics. I’ve been here since he was promoted and this is a first for him. He better hope his team delivers double digit growth this year and the pharmacies keep filling a branded generic at generic reimbursement. Otherwise, HK and JR could be looking at his activities too!
 






After the NSM, I think we can agree that this is the end for Amneal Specialty. HK and KS don’t understand the market and we will start to see our business fall. Where is the growth going to come from? Unithroid has very low margins of profit and when Rytary goes generic what will be left? Rytary is a better product then IPX if you look at the primary studies which that’s what insurance companies look at for reimbursement. It’s just a matter of time. Start planning your exit strategy before it’s too late.
 






Look! New alignment. Again. I guess they fired DS to cut headcount.
I agree with the above poster that this is the beginning of the end. At this point they are just gaining experience and titles They have not demonstrated an understanding of Specialty sales. KPI KPI KPI is all they know. Correlation does Not equal causation.
 






A reduction in headcount is coming in the guise of PIPs that will be given to some reps. and managers when PEs are delivered. Rytary will soon go generic. Endo can’t produce enough to pay the bills. There is panic at corporate. No one is safe.
 






















































Let's halt this discussion immediately and refrain from using this platform as a gossip thread regarding who is present or absent. Such behavior diminishes the purpose for which we are all here. Additionally, we may not be fully aware of the background stories behind what is happening. We are all aware of JR and HK's plans. Let's stop acting surprised about people leaving or being laid off; it's typical of NJ Pharma. Everyone should be seeking better opportunities. While this was a great place before JT's departure, we must acknowledge that it's not going to improve, and prioritize what's best for ourselves in the end. The people that moved on are the lucky ones at the end.
 






anonymous said:
Let's halt this discussion immediately and refrain from using this platform as a gossip thread regarding who is present or absent. Such behavior diminishes the purpose for which we are all here. Additionally, we may not be fully aware of the background stories behind what is happening. We are all aware of JR and HK's plans. Let's stop acting surprised about people leaving or being laid off; it's typical of NJ Pharma. Everyone should be seeking better opportunities. While this was a great place before JT's departure, we must acknowledge that it's not going to improve, and prioritize what's best for ourselves in the end. The people that moved on are the lucky ones at the end.
Click to expand...

Let’s not! These aren’t rumors and gossip. That list and the ones added are ones let go, for whatever reason, by this current regime. People need to see this in writing to understand the rest of your spot on analysis I don’t think these lists included those who left on their own initiative. THAT list would be at least double. All since JR and HK have taken over. To some this will come as a slow boil. People being let go here and there. But when you add up the names from the last 10 months it’s significant. We are not a big company. These are massive cuts in relation to scale.
You could not be more correct. You need to be planning your exit strategy now before they plan it for you.
 






People come onto Cafe P to find answers to questions they are afraid to ask or never get a truthful answer to. JD and HK both know that Rytary is not going to make it. That’s why you see them trimming the fat. They are reducing costs. Unithroid cannot support the entire specialty franchise. My prediction is that Amneal will focus on generics and biosimilars and Rytary in over seas markets. Rytary USA is on life support. The more increases in Unithroid share the greater likelihood that pharmacies will stop carrying a loss leader. Amneal will have to use a specialty pharmacy or contract with MCO’s. Amneal doesn’t want to do either and take a hit at profits. It’s going to be an interesting next 12 months. We will see what the verdict is on so many levels.
 






anonymous said:
Let's halt this discussion immediately and refrain from using this platform as a gossip thread regarding who is present or absent. Such behavior diminishes the purpose for which we are all here. Additionally, we may not be fully aware of the background stories behind what is happening. We are all aware of JR and HK's plans. Let's stop acting surprised about people leaving or being laid off; it's typical of NJ Pharma. Everyone should be seeking better opportunities. While this was a great place before JT's departure, we must acknowledge that it's not going to improve, and prioritize what's best for ourselves in the end. The people that moved on are the lucky ones at the end.
Click to expand...

No, what is happening here is not typical of NJ pharma, US Pharma, or pharma companies based over seas. Whistle blowers, non-compliance, glaring favoritism, age discrimination, terminations without merit, etc. It’s almost like the owners or aka senior leadership believe they are non-touchable.
 






anonymous said:
People come onto Cafe P to find answers to questions they are afraid to ask or never get a truthful answer to. JD and HK both know that Rytary is not going to make it. That’s why you see them trimming the fat. They are reducing costs. Unithroid cannot support the entire specialty franchise. My prediction is that Amneal will focus on generics and biosimilars and Rytary in over seas markets. Rytary USA is on life support. The more increases in Unithroid share the greater likelihood that pharmacies will stop carrying a loss leader. Amneal will have to use a specialty pharmacy or contract with MCO’s. Amneal doesn’t want to do either and take a hit at profits. It’s going to be an interesting next 12 months. We will see what the verdict is on so many levels.
Click to expand...

I’ve heard several people say something similar. Although I think they will keep endo with biosims and spin off PD This gives them some low paid flexibility to pick up some scraps and turn it into cash in the retail world. Joe and Chiraq said as much in CA.
 






Lost another sales rep today. I believe that makes 3 people this week. I guess when they say 1 Amneal that they really mean they only want 1 person AT Amneal.
Now people are learning about the Plans they’ve been put on, so look for the number of departures to dramatically increase the next 30-90 days. Which is exactly what you want when getting ready to launch a new drug. Nothing helps a launch succeed like chaos confusion and cuts!
 






They are not planning a launch right now. It’s a reduction in headcount without severance. Wait until all these Endo and PD reps. finish posting awards and promotions on LinkedIn. There will be a mass exodus of the employees they want to keep when they all find new positions. I guess they will backfill with inexperienced lower salaried contract reps. since they have already hired several of these.
 






anonymous said:
They are not planning a launch right now. It’s a reduction in headcount without severance. Wait until all these Endo and PD reps. finish posting awards and promotions on LinkedIn. There will be a mass exodus of the employees they want to keep when they all find new positions. I guess they will backfill with inexperienced lower salaried contract reps. since they have already hired several of these.
Click to expand...

we just ‘relaunched’ Ong. We are supposed to launch IPX Q3. They need to be in launch mode. But this is the pattern here. Last year we split into Spasticity right before we were supposed to launch IPX. I remember at the meeting some guy asked why we were cutting the sales force size right before a launch. Saying it had never been done before. I don’t remember the answer he got but I wonder if he’s still around. Now they are just forcing people out and either not replacing them or replacing them with less qualified people
 






Top Bottom
Back
Quote